Revtorpyk (Gedatolisib) FDA Approval: A New Treatment Option for HR+/HER2- Advanced Breast Cancer
Learn about Revtorpyk (gedatolisib), the FDA-approved treatment for HR+/HER2- advanced breast cancer, including its mechanism, clinical trial results, safety information, and patient considerations.
Introduction
The treatment landscape for advanced breast cancer continues to evolve as researchers develop therapies designed to target specific biological pathways involved in tumor growth. In July 2026, the U.S. Food and Drug Administration (FDA) approved Revtorpyk (gedatolisib), a targeted therapy developed by Celcuity Inc., for certain adults with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.
The approval provides a new treatment option for patients whose cancer does not have a detected PIK3CA mutation and whose disease has progressed after at least one line of endocrine therapy in the metastatic setting.
Revtorpyk represents an important development in cancer research because it is designed to block multiple components of the PI3K/AKT/mTOR pathway, a signaling network that plays a role in cancer cell growth, survival, and resistance to treatment.
Understanding HR+/HER2- Advanced Breast Cancer
Breast cancer is not a single disease. Doctors classify breast cancers based on biological characteristics that influence treatment decisions. HR-positive breast cancers contain hormone receptors that allow cancer cells to use hormones such as estrogen or progesterone to grow. HER2-negative breast cancers do not have high levels of the HER2 protein.
HR+/HER2- breast cancer is the most common breast cancer subtype, representing approximately 70% of breast cancer cases. Many patients initially receive endocrine therapies that reduce the effect of hormones on cancer cells. However, some advanced cancers eventually develop resistance and require additional treatment approaches.
In metastatic breast cancer, where cancer has spread to other parts of the body, researchers continue to explore targeted therapies that can delay disease progression and improve outcomes.
What Is Revtorpyk (Gedatolisib)?
Revtorpyk, also known by its active ingredient gedatolisib, is a kinase inhibitor that targets the PI3K/AKT/mTOR pathway. This pathway, sometimes referred to as the PAM pathway, regulates important cellular functions, including cell growth and survival.
Unlike some therapies that target only one part of this pathway, Revtorpyk inhibits all class I PI3K isoforms, including PI3K alpha, beta, delta, and gamma, as well as both mTORC1 and mTORC2 complexes.
By blocking multiple signaling points, the therapy aims to reduce cancer cell activity and limit pathways that may contribute to treatment resistance.
FDA Approval and Approved Use
The FDA approval of Revtorpyk applies to adults with:
- Hormone receptor positive (HR+) breast cancer
- HER2-negative breast cancer
- Locally advanced or metastatic disease
- No detected PIK3CA mutation
- Disease progression after at least one endocrine therapy in the metastatic setting
Revtorpyk is approved for use with fulvestrant, with or without palbociclib.
This approval was based on results from the Phase 3 VIKTORIA-1 clinical trial, which evaluated Revtorpyk combinations in patients with advanced HR+/HER2- breast cancer.
Clinical Trial Results from VIKTORIA-1
The VIKTORIA-1 trial was a global, randomized clinical study evaluating the effectiveness and safety of Revtorpyk combined with fulvestrant, with or without palbociclib.
In patients with PIK3CA wild-type advanced breast cancer, the combination of Revtorpyk, fulvestrant, and palbociclib showed a significant improvement in progression-free survival compared with fulvestrant alone.
Key findings included:
- The Revtorpyk combination with palbociclib and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone.
- Median progression-free survival was 9.3 months with the three-drug combination compared with 2.0 months with fulvestrant alone.
- The objective response rate was 32% with the Revtorpyk triplet combination compared with 1% with fulvestrant alone.
- The Revtorpyk and fulvestrant combination reduced the risk of progression or death by 67% compared with fulvestrant alone.
- Median progression-free survival was 7.4 months with the doublet combination compared with 2.0 months with fulvestrant alone.
These results suggest that Revtorpyk may provide another therapeutic option for patients with advanced HR+/HER2- breast cancer after progression on previous treatments.
How Revtorpyk Works
Cancer cells often rely on signaling pathways that regulate growth and survival. The PI3K/AKT/mTOR pathway is one of the most studied pathways in oncology because changes within this pathway can contribute to tumor development and resistance to therapy.
Revtorpyk works by inhibiting PI3K enzymes and mTOR complexes. This broad activity may help block several signals involved in cancer cell growth.
Researchers continue to study whether targeting multiple parts of this pathway can provide benefits across different cancer types and treatment settings.
Possible Side Effects and Safety Information
Like other cancer treatments, Revtorpyk may cause side effects. Patients receiving this medication should be monitored closely by their healthcare team.
Important warnings and precautions include:
Stomatitis
Revtorpyk can cause stomatitis, including mouth sores and oral inflammation. Clinical studies reported stomatitis in patients receiving Revtorpyk combinations. Preventive mouth care and monitoring may help manage this risk.
Skin Reactions
Some patients may develop rash or other skin-related reactions. Healthcare providers may recommend monitoring, treatment adjustments, or supportive care depending on severity.
Increased Blood Sugar Levels
Revtorpyk may cause hyperglycemia, or elevated blood glucose levels. Patients may require regular monitoring of fasting glucose and other diabetes-related measurements during treatment.
Pregnancy and Breastfeeding Considerations
Revtorpyk may cause harm to an unborn baby. People who may become pregnant should discuss contraception and pregnancy risks with their healthcare provider. Breastfeeding is not recommended during treatment and for the period advised after the final dose.
Future Research on Gedatolisib
Researchers are continuing to evaluate gedatolisib in additional clinical studies. Celcuity is investigating its potential use in other breast cancer treatment settings and other solid tumors.
Ongoing research includes studies exploring Revtorpyk in earlier treatment lines for HR+/HER2- advanced breast cancer and investigations involving metastatic castration-resistant prostate cancer.
Additional regulatory reviews and clinical studies may determine whether the treatment could become available for broader patient populations in the future.
What This Approval Means for Patients
The approval of Revtorpyk represents continued progress in personalized cancer medicine. Advanced breast cancer treatment increasingly focuses on understanding the specific biology of each tumor and selecting therapies that target important cancer pathways.
For eligible patients, Revtorpyk provides another option after progression following endocrine therapy. However, treatment decisions should always be made with an oncologist who can consider an individual’s medical history, previous treatments, tumor characteristics, and overall health.
Conclusion
Revtorpyk (gedatolisib) is a newly FDA-approved targeted therapy for adults with HR+/HER2- locally advanced or metastatic breast cancer without detected PIK3CA mutations after progression on endocrine therapy. By targeting multiple components of the PI3K/AKT/mTOR pathway, it represents a new approach in managing advanced breast cancer.
While clinical trial results are encouraging, patients should discuss potential benefits, risks, and alternatives with their healthcare providers. Continued research will help determine the long-term role of Revtorpyk in cancer treatment.
Disclaimer
This article is provided for educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Patients should consult qualified healthcare professionals before making decisions about medications, cancer treatment, or medical care.
Sources and References
- Celcuity Inc. FDA approval announcement for Revtorpyk (gedatolisib), July 2026.
- National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Breast Cancer Subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
- Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. International Journal of Breast Cancer. 2020.
- Venkatesan AM, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors. Journal of Medicinal Chemistry. 2010.
- Mallon R, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clinical Cancer Research. 2011.
- Rossetti S, et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. NPJ Breast Cancer. 2024.